Specialist life sciences venture capital investor Vesalius Biocapital has closed Vesalius Biocapital III at €120m (US$136.5m). This includes commitments of €30m from the European Investment Fund (EIF) and new and existing investors from Europe, the Americas and MENA. Vesalius Biocapital III is targeting later-stage European life science companies in drug development, medtech, diagnostics and digital…
©2019 All rights reserved LaingBuisson 
.){kind=link}